Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD‐L1, IDO, TIM‐3, FOXP3+ and CD8 expressions in patients with advanced esophageal squamous cell carcinoma

BACKGROUND: Anti‐PD‐1/PD‐L1 therapeutics have been widely used in the clinic in various tumors, including advanced esophageal cancer, showing remarkable treatment efficacy. Factors determining the response to anti‐PD‐1/PD‐L1 therapeutics are numerous, including the tumor microenvironment, such as CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shifa, Cai, Haibo, Huang, Junjun, Wang, Gongchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715848/
https://www.ncbi.nlm.nih.gov/pubmed/36288460
http://dx.doi.org/10.1111/1759-7714.14683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715848/
https://www.ncbi.nlm.nih.gov/pubmed/36288460
http://dx.doi.org/10.1111/1759-7714.14683

Ejemplares similares